US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Contineum Therapeutics, INC.

4.75

+0.600014.46%

Post-market: 4.750.00000.00%16:19 EDT

Volume:67.72K

Turnover:305.68K

Market Cap:122.89M

PE:-2.40

High:4.77

Open:4.16

Low:3.98

Close:4.15

Loading ...

Overview Company News Filings

Contineum Therapeutics Q4 2024 GAAP EPS $(0.56) Misses $(0.46) Estimate

Press Release: Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

BRIEF-Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Contineum Therapeutics Inc - Topline Data From Pipe-791 Phase 1B Trial Expected in Early 2026

THOMSON REUTERS

Contineum Therapeutics Initiates Patient Dosing in Phase 1B Chronic Pain Trial of Pipe-791

THOMSON REUTERS

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Contineum Therapeutics Price Target Maintained With a $31.00/Share by RBC Capital

Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from RBC Capital

Contineum Completes Enrollment in Trial for Relapsing-Remitting Multiple Sclerosis Treatment

MT Newswires Live

BRIEF-Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Contineum Therapeutics Completes Enrollment in Phase 2 Pipe-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (Rrms)

THOMSON REUTERS

BRIEF-Rapt Therapeutics Names Lori Lyons-Williams Chair Of The Board

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

THOMSON REUTERS

RAPT Therapeutics Inc - William Rieflin Steps Down as Chair, Remains Consultant

THOMSON REUTERS

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

Top Premarket Decliners

MT Newswires Live

Contineum Starts Patient Dosing in Positron Emission Tomography Trial

MT Newswires Live

BRIEF-Contineum Therapeutics Initiates Patient Dosing In Phase 1B Positron Emission Tomography (Pet) Trial Of Pipe-791

Contineum initiates patient dosing in Phase 1B PET trial

Contineum Therapeutics Initiates Patient Dosing in Phase 1B Positron Emission Tomography (Pet) Trial of Pipe-791

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTNM/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTNM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTNM\",,,,,undefined,":{"symbol":"CTNM","market":"US","secType":"STK","nameCN":"Contineum Therapeutics, INC.","latestPrice":4.75,"timestamp":1749240000000,"preClose":4.15,"halted":0,"volume":67719,"hourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.75,"latestTime":"16:19 EDT","volume":1185,"amount":5635.65,"timestamp":1749241198526},"delay":0,"floatShares":13167143,"shares":25871549,"eps":-1.975239,"marketStatus":"Market Closed","change":0.6,"latestTime":"06-06 16:00:00 EDT","open":4.16,"high":4.765,"low":3.98,"amount":305680.9423,"amplitude":0.189157,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.975239,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":4.15,"preHourTrading":{"tag":"盘前","latestPrice":4.19,"preClose":4.15,"latestTime":"09:29 EDT","volume":30,"amount":125.79999,"timestamp":1749216590034},"postHourTrading":{"tag":"盘后","latestPrice":4.75,"preClose":4.75,"latestTime":"16:19 EDT","volume":1185,"amount":5635.65,"timestamp":1749241198526},"volumeRatio":0.36693762911708244,"impliedVol":0.7834,"impliedVolPercentile":0.2195},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTNM\",,,,,undefined,":{"symbol":"CTNM","floatShares":13167143,"roa":"-22.94%","roe":"-33.03%","lyrEps":-2.183553,"volumeRatio":0.36693762911708244,"shares":25871549,"dividePrice":0,"high":4.765,"amplitude":0.189157,"preClose":4.15,"low":3.98,"week52Low":3.35,"pbRate":"0.67","week52High":22,"institutionHeld":0,"latestPrice":4.75,"eps":-1.975239,"divideRate":0,"volume":67719,"delay":0,"ttmEps":-1.975239,"open":4.16,"prevYearClose":14.65,"prevWeekClose":3.66,"prevMonthClose":3.66,"prevQuarterClose":6.98,"fiveDayClose":3.66,"twentyDayClose":3.95,"sixtyDayClose":7.56},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTNM\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517135551","title":"Contineum Therapeutics Q4 2024 GAAP EPS $(0.56) Misses $(0.46) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2517135551","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517135551?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:12","pubTimestamp":1741295527,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.46) by 21.74 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44179637/contineum-therapeutics-q4-2024-gaap-eps-0-56-misses-0-46-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CTNM"],"gpt_icon":0},{"id":"2517210118","title":"Press Release: Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2517210118","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517210118?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:05","pubTimestamp":1741295100,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones. - Topline data from PIPE-791 Phase 1b positron emission tomography  trial expected in the second quarter of 2025. - Topline data from PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis  anticipated in the second half of 2025. Contineum Therapeutics, Inc.  , a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology  indications, today reported its fourth-quarter 2024 financial results and affirmed its key clinical development milestones.\"2025 is shaping up to be a pivotal year, as we have several important clinical data readouts and trial initiations on the horizon,\" said Carmine Stengone, CEO, Contineum Therapeutics. \"We expect to be sponsoring up to six clinical trials during the course of the year, with key topline data from our PIPE-791 Phase 1b posi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","IE00BFTCPJ56.SGD","LU1778281490.HKD","LU0345769631.USD","SG9999001440.SGD","IE00BVYPNW00.USD","LU0203347892.USD","LU2129689605.HKD","BK4559","LU1066053197.SGD","IE000M9KFDE8.USD","LU0234572021.USD","BK4585","LU1162221912.USD","LU2129689431.USD","JNJ","LU0640476718.USD","LU0345769128.USD","BK4192","LU0320765646.SGD","IE00BVYPNV92.GBP","IE0002141913.USD","IE00BSNM7G36.USD","LU2129689514.USD","LU2430703095.HKD","LU0114720955.EUR","LU1244550221.USD","LU1914381329.SGD","LU2505996681.GBP","IE0009355771.USD","BK4550","LU1261432733.SGD","LU0792757196.USD","LU0234570918.USD","CTNM","IE0034235303.USD","LENZ","BK4504","LU1244550494.USD","LU0345770993.USD","IE00B7SZLL34.SGD","LU1732800096.USD","LU1061106388.HKD","LU2592432038.USD","BK4532","PET","LU1196500208.SGD","LU1244550577.SGD","BK4007","LU1267930813.SGD"],"gpt_icon":0},{"id":"2517984500","title":"BRIEF-Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791","url":"https://stock-news.laohu8.com/highlight/detail?id=2517984500","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517984500?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:54","pubTimestamp":1741125286,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791March 4 (Reuters) - Contineum Therapeutics Inc CTNM.O:CONTINEUM THERAPEUTICS INITIATES PATIENT DOSING IN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA6Z9DMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2517989304","title":"Contineum Therapeutics Inc - Topline Data From Pipe-791 Phase 1B Trial Expected in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2517989304","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517989304?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:05","pubTimestamp":1741122302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA6Z9DMN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2517276986","title":"Contineum Therapeutics Initiates Patient Dosing in Phase 1B Chronic Pain Trial of Pipe-791","url":"https://stock-news.laohu8.com/highlight/detail?id=2517276986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517276986?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:05","pubTimestamp":1741122302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA6Z9DMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2516561666","title":"Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2516561666","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516561666?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:05","pubTimestamp":1741035900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 03, 2025----Contineum Therapeutics, Inc.  , a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology  indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.Contineum Therapeutics  is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/contineum-therapeutics-present-2025-leerink-210500502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","LENZ","BK4139","CTNM","BK4007","HCSG"],"gpt_icon":0},{"id":"2502092045","title":"Contineum Therapeutics Price Target Maintained With a $31.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2502092045","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502092045?lang=en_us&edition=fundamental","pubTime":"2025-01-09 23:31","pubTimestamp":1736436660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CTNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2025 10:31 ET (15:31 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CTNM"],"gpt_icon":0},{"id":"2502013062","title":"Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2502013062","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502013062?lang=en_us&edition=fundamental","pubTime":"2025-01-09 19:55","pubTimestamp":1736423722,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) yesterday and set a pri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/contineum-therapeutics-inc-class-a-ctnm-receives-a-buy-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/contineum-therapeutics-inc-class-a-ctnm-receives-a-buy-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","BK4007","CTNM"],"gpt_icon":0},{"id":"2502081259","title":"Contineum Completes Enrollment in Trial for Relapsing-Remitting Multiple Sclerosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2502081259","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502081259?lang=en_us&edition=fundamental","pubTime":"2025-01-09 06:37","pubTimestamp":1736375873,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics  completed the enrollment of 168 patients in its phase 2 PIPE-307 VISTA trial for the treatment of relapsing-remitting multiple sclerosis.The trial is designed to assess safety and efficacy by evaluating multiple clinical and imaging endpoints sensitive to remyelination changes in RRMS patients, the company said. The last patient is expected to complete the trial by Q3.PIPE-307 is being developed under a global license and development agreement between Continuum and Janssen Pharmaceutica, a unit of Johnson & Johnson .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765646.SGD","LU1894683264.USD","LU0792757196.USD","LU1244550494.USD","LU0795875086.SGD","LU0882574055.USD","LU1914381329.SGD","IE00B4R5TH58.HKD","IE00B19Z3B42.SGD","IE00BVYPNW00.USD","IE00B42XCP33.USD","LU2089984988.USD","SG9999002224.SGD","LU0234572021.USD","LU0912757837.SGD","LU1267930813.SGD","JNJ","LU1074936037.SGD","LU0345770993.USD","LU1059921491.USD","LU0345770308.USD","LU1929549753.HKD","LU0640476718.USD","LU0122379950.USD","BK4533","LU1778281490.HKD","LU1718418525.SGD","LU0466842654.USD","LU1221951046.USD","IE0034235303.USD","SG9999001440.SGD","CTNM","LU1244550221.USD","LU0345769128.USD","LU0058720904.USD","LU1162221912.USD","IE00BVYPNV92.GBP","LU1732800096.USD","LU1066053197.SGD","IE000M9KFDE8.USD","LU1221951129.SGD","LU1023059063.AUD","LU0114720955.EUR","BK4534","LU1430594728.SGD","BK4592","SG9999002232.USD","IE00BJT1NW94.SGD","LU0098860793.USD","LU1057294990.SGD"],"gpt_icon":0},{"id":"2502083502","title":"BRIEF-Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502083502","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502083502?lang=en_us&edition=fundamental","pubTime":"2025-01-09 05:12","pubTimestamp":1736370760,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)Jan 8 (Reuters) - Contineum Therapeutics Inc CTNM.O:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA77JNBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2502508804","title":"Contineum Therapeutics Completes Enrollment in Phase 2 Pipe-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (Rrms)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502508804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502508804?lang=en_us&edition=fundamental","pubTime":"2025-01-09 05:05","pubTimestamp":1736370301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA77JNBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2501239733","title":"BRIEF-Rapt Therapeutics Names Lori Lyons-Williams Chair Of The Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239733","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239733?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:11","pubTimestamp":1736169075,"startTime":"0","endTime":"0","summary":"BRIEF-Rapt Therapeutics Names Lori Lyons-WilliamsChair Of The BoardJan 6  - Contineum Therapeutics Inc CTNM.O:RAPT THERAPEUTICS NAMES LORI LYONS-WILLIAMS CHAIR OF THE COMPANY’S BOARD OF DIRECTORSRAPT THERAPEUTICS INC - WILLIAM RIEFLIN STEPS DOWN AS CHAIR, REMAINS CONSULTANTSource text: nGNX9jzGlFurther company coverage: CTNM.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA1RY7B3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RAPT","CTNM","BK4007"],"gpt_icon":0},{"id":"2501312239","title":"RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2501312239","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501312239?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA1RY7B3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CTNM","RAPT","BK4007"],"gpt_icon":0},{"id":"2501239310","title":"RAPT Therapeutics Inc - William Rieflin Steps Down as Chair, Remains Consultant","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239310?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA1RY7B3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RAPT","CTNM","BK4007"],"gpt_icon":0},{"id":"2501399512","title":"RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2501399512","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501399512?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025  -- RAPT Therapeutics, Inc. , a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company.About RAPT Therapeutics, Inc.RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with inflammatory and immunological diseases. The company leverages its proprietary discovery and development platform to advance both biologics and sele","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rapt-therapeutics-names-lori-lyons-130000576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0345780950.USD","LU1621767810.EUR","LU0345781412.USD","IE00BLSP4452.SGD","LU0266512127.USD","LU1621768206.USD","LU2384288077.EUR","LU0070302665.USD","WMB","LU0788109394.HKD","LU0630314457.HKD","BK4585","BK4139","LU1621768115.EUR","LU2237443978.SGD","IE00BN8TJ469.HKD","LU0368265418.SGD","LU0300736062.USD","LU2237443549.SGD","BK4588","CTNM","LU0122376428.USD","IE00BLSP4239.USD","LU0320765489.SGD","LU0208291251.USD","LU0300736492.USD","LU1621767737.EUR","BK4007","IE00BBT3K403.USD","BK4144","LU2237443622.USD","RAPT","LU0456854461.SGD","LU2237443382.USD"],"gpt_icon":0},{"id":"2494025768","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2494025768","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494025768?lang=en_us&edition=fundamental","pubTime":"2024-12-27 20:40","pubTimestamp":1735303253,"startTime":"0","endTime":"0","summary":"Mannatech  shares were down 17% pre-bell Friday, adding to Thursday's losses.Contineum Therapeutics  shares fell 16% following a muted session.Curbline Properties  shares dropped 15% after closing nearly flat on Thursday.Addex Therapeutics  shares retreated 15% following a 1.1% loss in the previous session.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4183","ADXN","CTNM","BK4007","BK4231","MTEX","BK4139","CURB","BK4563"],"gpt_icon":0},{"id":"2492624639","title":"Contineum Starts Patient Dosing in Positron Emission Tomography Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492624639","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492624639?lang=en_us&edition=fundamental","pubTime":"2024-12-17 06:58","pubTimestamp":1734389908,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics  reported late Monday dosing of the first cohort of patients in the PIPE-791 phase 1b positron emission tomography trial.The study is expected to measure the correlation of pharmacokinetics to receptor occupancy by positron emission tomography imaging in healthy volunteers, as well as idiopathic pulmonary fibrosis and progressive multiple sclerosis patients, it said.Contineum said it expects topline data from the trial in Q2 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2492662882","title":"BRIEF-Contineum Therapeutics Initiates Patient Dosing In Phase 1B Positron Emission Tomography (Pet) Trial Of Pipe-791","url":"https://stock-news.laohu8.com/highlight/detail?id=2492662882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492662882?lang=en_us&edition=fundamental","pubTime":"2024-12-17 05:21","pubTimestamp":1734384071,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Initiates Patient Dosing In Phase 1B Positron Emission Tomography (Pet) Trial Of Pipe-791Dec 16 (Reuters) - Contineum Therapeutics Inc CTNM.O:CONTINEUM THERAPEUTICS INITIA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nTUA96B0BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2492640239","title":"Contineum initiates patient dosing in Phase 1B PET trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492640239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492640239?lang=en_us&edition=fundamental","pubTime":"2024-12-17 05:11","pubTimestamp":1734383485,"startTime":"0","endTime":"0","summary":"Contineum (CTNM) Therapeutics “announced dosing of the first cohort of patients in the PIPE-791 Phase 1b positron emission tomography, PET, trial. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/contineum-initiates-patient-dosing-in-phase-1b-pet-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/contineum-initiates-patient-dosing-in-phase-1b-pet-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","BK4007","PET","BK4192"],"gpt_icon":0},{"id":"2492640372","title":"Contineum Therapeutics Initiates Patient Dosing in Phase 1B Positron Emission Tomography (Pet) Trial of Pipe-791","url":"https://stock-news.laohu8.com/highlight/detail?id=2492640372","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492640372?lang=en_us&edition=fundamental","pubTime":"2024-12-17 05:05","pubTimestamp":1734383100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nTUA96B0BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CTNM"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTNM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"CTNM","fiscalQuarterEnding":"2025/03","expectedEps":-0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.62}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTNM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTNM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1741924800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTNM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTNM","date":"2025-06-06","current":-2.154621,"percent":0.694545,"low":-16.425726,"twenty":-13.448154,"median":-4.770625,"eighty":17.122563,"high":28.322904,"avg":-1.006749,"sd":13.685568,"marketCap":107366928},"quantilePoints":[{"date":"2024-04-05","current":16.281367,"twenty":16.281367,"median":16.281367,"eighty":16.281367,"marketCap":369912656},{"date":"2024-04-12","current":17.609251,"twenty":16.281367,"median":16.569509,"eighty":16.868158,"marketCap":400082176},{"date":"2024-04-19","current":17.122563,"twenty":16.281367,"median":16.868158,"eighty":17.144685,"marketCap":389024629},{"date":"2024-04-26","current":17.686678,"twenty":16.315104,"median":17.089379,"eighty":17.59819,"marketCap":401841332},{"date":"2024-05-03","current":16.48102,"twenty":16.48102,"median":17.122563,"eighty":17.59819,"marketCap":374448771},{"date":"2024-05-10","current":17.719862,"twenty":16.38147,"median":17.105971,"eighty":17.59819,"marketCap":402595255},{"date":"2024-05-17","current":16.547386,"twenty":16.392531,"median":17.100441,"eighty":17.487579,"marketCap":375956618},{"date":"2024-05-24","current":17.819411,"twenty":16.48102,"median":17.133624,"eighty":17.59819,"marketCap":404857026},{"date":"2024-05-31","current":20.173009,"twenty":16.534113,"median":17.172337,"eighty":17.68889,"marketCap":385849140},{"date":"2024-06-07","current":21.67926,"twenty":16.768608,"median":17.354846,"eighty":18.209439,"marketCap":414659209},{"date":"2024-06-14","current":22.311348,"twenty":16.85046,"median":17.388029,"eighty":20.619504,"marketCap":426749148},{"date":"2024-06-21","current":26.466988,"twenty":16.894704,"median":17.487579,"eighty":21.17897,"marketCap":506234071},{"date":"2024-06-28","current":25.216261,"twenty":16.921251,"median":17.542884,"eighty":21.517876,"marketCap":482311425},{"date":"2024-07-05","current":27.018383,"twenty":16.987617,"median":17.609251,"eighty":21.78147,"marketCap":516780614},{"date":"2024-07-12","current":28.242212,"twenty":17.042923,"median":17.692208,"eighty":22.916538,"marketCap":540188796},{"date":"2024-07-15","current":27.932893,"twenty":17.049559,"median":17.697739,"eighty":23.766494,"marketCap":534272442},{"date":"2024-08-02","current":26.224911,"twenty":17.056196,"median":17.697739,"eighty":24.100021,"marketCap":501603882},{"date":"2024-08-09","current":22.338245,"twenty":17.08938,"median":17.819411,"eighty":24.409341,"marketCap":427263614},{"date":"2024-08-16","current":-15.206885,"twenty":17.023013,"median":17.769636,"eighty":24.100021,"marketCap":478195700},{"date":"2024-08-23","current":-14.92058,"twenty":16.547386,"median":17.697739,"eighty":23.683112,"marketCap":469192554},{"date":"2024-08-30","current":-15.468649,"twenty":16.315104,"median":17.614781,"eighty":23.293101,"marketCap":486427149},{"date":"2024-09-06","current":-14.511573,"twenty":15.417858,"median":17.570537,"eighty":22.830467,"marketCap":456330916},{"date":"2024-09-13","current":-14.765157,"twenty":-14.025672,"median":17.410151,"eighty":22.682531,"marketCap":464305131},{"date":"2024-09-20","current":-16.425726,"twenty":-14.408503,"median":17.365907,"eighty":22.459283,"marketCap":516523382},{"date":"2024-09-27","current":-15.272326,"twenty":-14.745525,"median":17.19999,"eighty":22.405488,"marketCap":480253562},{"date":"2024-10-04","current":-14.421591,"twenty":-14.887859,"median":17.133624,"eighty":22.351694,"marketCap":453501355},{"date":"2024-10-11","current":-13.521775,"twenty":-14.788061,"median":17.100441,"eighty":22.316727,"marketCap":425205752},{"date":"2024-10-18","current":-13.480875,"twenty":-14.745525,"median":17.039604,"eighty":22.010098,"marketCap":423919588},{"date":"2024-10-25","current":-13.309092,"twenty":-14.662087,"median":16.868158,"eighty":21.934785,"marketCap":418517700},{"date":"2024-10-31","current":-14.004404,"twenty":-14.595828,"median":16.547386,"eighty":21.78147,"marketCap":440382485},{"date":"2024-11-08","current":-13.455721,"twenty":-14.532841,"median":16.387,"eighty":21.655052,"marketCap":477166769},{"date":"2024-11-15","current":-13.193473,"twenty":-14.477216,"median":16.281367,"eighty":21.566291,"marketCap":467866942},{"date":"2024-11-22","current":-10.423934,"twenty":-14.434679,"median":15.167037,"eighty":21.517876,"marketCap":369653551},{"date":"2024-11-29","current":-10.838275,"twenty":-14.411775,"median":-9.795154,"eighty":21.388769,"marketCap":384346893},{"date":"2024-12-06","current":-10.358512,"twenty":-14.347406,"median":-10.271282,"eighty":21.17897,"marketCap":367333550},{"date":"2024-12-13","current":-10.031401,"twenty":-14.270231,"median":-10.358512,"eighty":21.154762,"marketCap":355733543},{"date":"2024-12-20","current":-9.70429,"twenty":-14.217087,"median":-10.242206,"eighty":20.950342,"marketCap":344133536},{"date":"2024-12-27","current":-10.569317,"twenty":-14.14183,"median":-10.271282,"eighty":20.635643,"marketCap":374809110},{"date":"2025-01-03","current":-10.525702,"twenty":-14.135286,"median":-10.358512,"eighty":20.603366,"marketCap":373262442},{"date":"2025-01-10","current":-9.718828,"twenty":-14.073857,"median":-10.358512,"eighty":20.25908,"marketCap":344649092},{"date":"2025-01-17","current":-9.071876,"twenty":-14.047944,"median":-10.256744,"eighty":19.850241,"marketCap":321706856},{"date":"2025-01-24","current":-8.19958,"twenty":-14.045305,"median":-10.209494,"eighty":18.599466,"marketCap":290773505},{"date":"2025-01-31","current":-7.429052,"twenty":-14.035488,"median":-10.009594,"eighty":17.759682,"marketCap":263449044},{"date":"2025-02-07","current":-6.883867,"twenty":-14.024036,"median":-9.925999,"eighty":17.706588,"marketCap":244115699},{"date":"2025-02-14","current":-5.589962,"twenty":-14.010948,"median":-9.718828,"eighty":17.697739,"marketCap":198231228},{"date":"2025-02-21","current":-5.742614,"twenty":-13.988044,"median":-9.667944,"eighty":17.693315,"marketCap":203644564},{"date":"2025-02-28","current":-5.19016,"twenty":-13.940599,"median":-9.518928,"eighty":17.660132,"marketCap":184053442},{"date":"2025-03-07","current":-3.942751,"twenty":-13.847345,"median":-9.071876,"eighty":17.615888,"marketCap":166612775},{"date":"2025-03-14","current":-4.371311,"twenty":-13.716463,"median":-8.19958,"eighty":17.604827,"marketCap":184722859},{"date":"2025-03-21","current":-4.377433,"twenty":-13.63957,"median":-8.126889,"eighty":17.576068,"marketCap":184981575},{"date":"2025-03-28","current":-4.561102,"twenty":-13.619937,"median":-7.567165,"eighty":17.520762,"marketCap":192743040},{"date":"2025-04-04","current":-3.75296,"twenty":-13.617995,"median":-7.116479,"eighty":17.456608,"marketCap":158592595},{"date":"2025-04-11","current":-2.528503,"twenty":-13.600664,"median":-6.847522,"eighty":17.401302,"marketCap":106849497},{"date":"2025-04-17","current":-2.681561,"twenty":-13.574128,"median":-6.436815,"eighty":17.385817,"marketCap":113317384},{"date":"2025-04-25","current":-2.767272,"twenty":-13.55286,"median":-5.742614,"eighty":17.372544,"marketCap":116939401},{"date":"2025-05-02","current":-2.430547,"twenty":-13.541408,"median":-5.640845,"eighty":17.334936,"marketCap":102710049},{"date":"2025-05-09","current":-2.418302,"twenty":-13.513595,"median":-5.553616,"eighty":17.244235,"marketCap":102192618},{"date":"2025-05-16","current":-2.045592,"twenty":-13.477603,"median":-5.430041,"eighty":17.188929,"marketCap":101933903},{"date":"2025-05-23","current":-2.030017,"twenty":-13.462755,"median":-5.321004,"eighty":17.144685,"marketCap":101157756},{"date":"2025-05-30","current":-1.853493,"twenty":-13.455721,"median":-5.117468,"eighty":17.144685,"marketCap":92361429},{"date":"2025-06-06","current":-2.154621,"twenty":-13.448154,"median":-4.770625,"eighty":17.122563,"marketCap":107366928}],"updateTime":1749424770497}}}